| Dr Paul V Birinyi, MD | |
|
2410 Jake Dr Ste 1, Opelousas, LA 70570-7710 | |
| (800) 238-0827 | |
| (318) 219-5221 |
| Full Name | Dr Paul V Birinyi |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 14 Years |
| Location | 2410 Jake Dr Ste 1, Opelousas, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851603906 | NPI | - | NPPES |
| 2483978 | Medicaid | LA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stormont Vail Hospital | Topeka, KS | Hospital |
| Opelousas General Health System | Opelousas, LA | Hospital |
| Lafayette General Medical Center | Lafayette, LA | Hospital |
| Our Lady Of Lourdes Regional Medical Center, Inc | Lafayette, LA | Hospital |
| Entity Name | Performance Spine And Brain |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104586916 PECOS PAC ID: 7810388006 Enrollment ID: O20211223000061 |
News Archive
The landmark "Sexual Behavior in the Human Male" report revealed major insights into bisexual behavior and orientation - without even using the word "bisexual" - when it was published 60 years ago by pioneering sex researcher Alfred Kinsey and his research team at Indiana University.
A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning, a decline that may impact their survival, a new study by investigators at Dana-Farber Cancer Institute and Brigham and Women's Hospital indicates.
Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC's proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.
The antibacterial ingredient in some soaps, toothpastes, odor-fighting socks, and even computer keyboards is pointing scientists toward a long-sought new treatment for a parasitic disease that affects almost two billion people. Their report on how triclosan became the guiding light for future development of drugs for toxoplasmosis appears in ACS' monthly Journal of Medicinal Chemistry.
Results of a phase I clinical trial of the Sanaria PfSPZ Vaccine to combat malaria, published today in the online issue of Science magazine, show that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites. Plasmodium falciparum is the malaria parasite that causes more than 600,000 deaths annually.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul V Birinyi, MD Po Box 11758, Alexandria, LA 71315-1758 Ph: (800) 238-0827 | Dr Paul V Birinyi, MD 2410 Jake Dr Ste 1, Opelousas, LA 70570-7710 Ph: (800) 238-0827 |
News Archive
The landmark "Sexual Behavior in the Human Male" report revealed major insights into bisexual behavior and orientation - without even using the word "bisexual" - when it was published 60 years ago by pioneering sex researcher Alfred Kinsey and his research team at Indiana University.
A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning, a decline that may impact their survival, a new study by investigators at Dana-Farber Cancer Institute and Brigham and Women's Hospital indicates.
Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC's proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.
The antibacterial ingredient in some soaps, toothpastes, odor-fighting socks, and even computer keyboards is pointing scientists toward a long-sought new treatment for a parasitic disease that affects almost two billion people. Their report on how triclosan became the guiding light for future development of drugs for toxoplasmosis appears in ACS' monthly Journal of Medicinal Chemistry.
Results of a phase I clinical trial of the Sanaria PfSPZ Vaccine to combat malaria, published today in the online issue of Science magazine, show that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites. Plasmodium falciparum is the malaria parasite that causes more than 600,000 deaths annually.
› Verified 1 days ago